Could 6 months of targeted therapy be enough for some breast cancer patients?

This study looks at whether women with early-stage HER2-positive breast cancer who have a complete response to initial chemotherapy and targeted therapy can safely receive only 6 months of additional targeted therapy instead of the standard 12 months. The goal is to reduce side effects, treatment burden, and costs while maintaining effectiveness. About 52 participants across multiple Canadian centers will be enrolled to see if this shorter approach is feasible and safe.